Ukrainian Journal Health of Woman. 2026. 2(183): 5-9. doi: 10.15574/HW.2026.2(183).59
Zarichanska K. V.¹, Gvozdecka G. S.², Yemets N. O.^3
1Shupyk National Healthcare University of Ukraine, Kyiv
²Ivano-Frankivsk National Medical University, Ukraine
³KNP ‘Consultative and Diagnostic Center’ of the Obolonsky district of Kyiv, Ukraine

For citation: Zarichanska KV, Gvozdecka GS, Yemets NO. (2026). Optimization of the tactics of managing pregnant women with placental dysfunction. Ukrainian Journal Health of Woman. 2(183): 5-9. doi: 10.15574/HW.2026.2(183).59
Article received: Feb 13, 2026. Accepted for publication: Mar 22, 2026.

Aim – to investigate the effectiveness of the use of lecithin-standard (Lipin-Biolik) in the complex treatment of pregnant women with placental dysfunction.
Materials and methods. 60 pregnant women aged 26.7±0.5 years with gestational age of 30-34 weeks with placental dysfunction were examined. All pregnant women were divided into 2 groups. In group I (30 women) in addition to the generally accepted therapy of placental dysfunction lecithin-standard (Lipin-Biolik) was additionally prescribed in the form of intravenous injections at a dose of 5-10 mg/kg of body weight once a day for 5 days. Pregnant women of group II (30 women) received standard therapy for placental dysfunction. The state of uteroplacental-fetal blood flow was investigated using Dopplerometry. Cardiotocography (CTG) was performed according to the Dawes–Redman criteria, and the indicators of the fetal biophysical profile (BPP) were assessed using ultrasound and CTG.
The results of Dopplerometry before treatment revealed impaired uteroplacental-fetal blood flow with increased vascular resistance. An equivocal  result of BPP (score 5-6 points) was observed in 12 (40.0%) pregnant women of group I and 13 (43.3%) pregnant women of group II. The results of the study showed the effectiveness of the proposed therapy of placental dysfunction using lecithin-standard (Lipin-Biolik). After the course of treatment, clinical manifestations of placental dysfunction were eliminated in pregnant women of group I, while in group II, manifestations of placental dysfunction persisted in 4 (13.3%) patients. In this regard, in 2 (6.7%) cases in group II, premature birth occurred at 35 and 36 weeks of pregnancy. Newborns from mothers of group I had better Apgar scores. Small-for-gestational-age was observed in 5 (16.7%) newborns from mothers of group II and 2 (6.7%) children from mothers of group I.
Conclusions. Adding lecithin-standard (Lipin-Biolik) to the standard therapy for placental dysfunction eliminates the clinical manifestations of placental dysfunction and prevents the development of fetal growth retardation.
The study was carried out in accordance with the principles of the Declaration of Helsinki. The informed consent of the patients was obtained for the study.
No conflict of interest was declared by the authors.
Keywords: pregnancy, placental dysfunction, uteroplacental-fetal blood flow, Dopplerometry, treatment, lecithin-standard.

REFERENCES

1. Aye ILMH, Tong S, Charnock-Jones DS, Smith GCS. (2025). The human placenta and its role in reproductive outcomes revisited. Physiological reviews. 105(4): 2305-2376. https://doi.org/10.1152/physrev.00039.2024; PMid:40497429 PMCid:PMC7617900

2. Instruktsiia dlia medychnoho zastosuvannia likarskoho zasobu LIPIN-BIOLIK. https://biolik.com.ua/product/lipin-biolik/.

3. Kingdom JC, Audette MC, Hobson SR, Windrim RC, Morgen E. (2018). A placenta clinic approach to the diagnosis and management of fetal growth restriction. American journal of obstetrics and gynecology. 218(2): S803-S817. https://doi.org/10.1016/j.ajog.2017.11.575; PMid:29254754

4. Kravchenko O. (2021). Algorithm for the diagnosis and treatment of primary placental dysfunction in pregnant women of risk groups. Reproductive endocrinology. (61): 33-38. https://doi.org/10.18370/2309-4117.2021.61.33-38

5. Kudina O.V. (2013). Eksperymentalne doslidzhennia vplyvu preparatu lipin na stan leheniv plodiv shchuriv na modeli platsentarnoi dysfunktsii. V kn.: O.V. Kudina. Problemy ekolohichnoi ta medychnoi henetyky i klinichnoi imunolohii. Vyp. 6: 194-199. URL: http://nbuv.gov.ua/UJRN/pemgki_2013_6_23.

6. Mazarico E, Molinet-Coll C, Martinez-Portilla RJ, Figueras F. (2020). Heparin therapy in placental insufficiency: Systematic review and meta-analysis. Acta obstetricia et gynecologica Scandinavica. 99(2): 167-174. https://doi.org/10.1111/aogs.13730; PMid:31519033

7. MOZ Ukrainy. (2023). Pro zatverdzhennia Standartu medychnoi dopomohy «Zatrymka rostu ploda». Nakaz MOZ Ukrainy vid 02.10.2023 No. 1718.

8. Nazarenko LH, Huk LO, Nestertsova NS. (2020). Bazovi aspekty otsiniuvannia stanu ploda i prohnozuvannia zdorov'ia novonarodzhenoho. Zdorovia zhinky. № 5-6: 8-14.

9. Preston M, Hall M, Shennan A, Story L. (2024). The role of placental insufficiency in spontaneous preterm birth: A literature review. European journal of obstetrics, gynecology, and reproductive biology. 295: 136-142. https://doi.org/10.1016/j.ejogrb.2024.02.020; PMid:38359634

10. Romanenko TG. (2017). Placental dysfunction as a predictor of miscarriage. Reproductive endocrinology. (33): 77-82. https://doi.org/10.18370/2309-4117.2017.33.77-82

11. Sultana Z, Qiao Y, Maiti K, Smith R. (2023). Involvement of oxidative stress in placental dysfunction, the pathophysiology of fetal death and pregnancy disorders. Reproduction (Cambridge, England). 166(2): R25-R38. https://doi.org/10.1530/REP-22-0278; PMid:37318094

12. Sun C, Groom KM, Oyston C, Chamley LW, Clark AR, James JL. (2020). The placenta in fetal growth restriction: What is going wrong? Placenta. 96: 10-18. https://doi.org/10.1016/j.placenta.2020.05.003; PMid:32421528

13. Symrok VV, Hryshchenko OV, Zaichenko HV ta in. (2009). Liposomalna forma fosfatydylkholinu: kliniko-farmakolohichne obgruntuvannia vykorystannia v akusherskii praktytsi. Ukr. tsentr nauk. med. inform. i patentno-litsenziinoi roboty. Kyiv: 42.

14. Zaichenko HV, Kudina OV. (2008). Fetoprotektorna diia lipinu: morfolohichni aspekty. Pediatriia, akusherstvo ta hinekolohiia. 5: 104-108.